联合检测血清Cyfra21-1、CK19-2G2在非小细胞肺癌患者中的诊断

Clinical diagnostic value of combined detection of serum Cyfra 21-1 and CK19-2G2 in patients with non-small cell lung cancer

目的:探讨联合检测血清Cyfra 21-1、CK19-2G2在非小细胞肺癌患者中的诊断。方法:采用化学发光免疫法检测92例非小细胞肺癌患者、83例肺部良性疾病患者和90例健康体检者血清Cyfra 21-1、CK19-2G2的浓度,并判断两者的相关性。比较单独与联合检测Cyfra21-1、CK19-2G2对于诊断非小细胞肺癌的灵敏度和特异性。结果:非小细胞肺癌组血清Cyfra 21-1、CK19-2G2水平显著高于肺部良性疾病组和健康对照组(P<0.01);非小细胞肺癌患者血清Cyfra 21-1与CK19-2G2水平呈正相关性(P<0.05)。两者联合诊断非小细胞肺癌的灵敏度为82.7%、特异性为78%。结论:Cyfra 21-1、CK19-2G2是有效的诊断非小细胞肺癌的肿瘤标志物。血清Cyfra 21-1、CK19-2G2水平在非小细胞肺癌的诊断中有临床应用价值,两者联合检测的灵敏度和特异性高。

Objective：To investigate the clinical diagnostic value of the combined detection of serum Cyfra 21-1 and CK19-2G2 in patients with the non-small cell lung cancer （ NSCLC ） . Methods：The levels of serum Cyfra 21-1 and CK19-2G2 in 92 cases of NSCLC,83 of benign lung diseases and 90 of healthy controls were detected by chemiluminescent immunoassay. And the correlation between Cyfra 21-1 and CK19-2G2 was evaluated.Moreover,the sensitivity and specificity of combined detection of serum Cyfra 21-1 and CK19-2G2 for of the diagnosis of the NSCLC was compared with detection of either alone.Results：The Cyfra 21-1 and CK19-2G2 levels in serum of the NSCLC patients were significantly higher than those with benign lung disease and healthy controls （P〈0.01）.The Cyfra 21-1 and CK19-2G2 levels of the NSCLC patients were positively correlated （P〈0. 05）.Combined detection of both biomarkers in NSCLC yielded a sensitivity of 82.7% and a specificity of 78%. Conclusions：Cyfra 21-1 and CK19-2G2 are effective tumor markers for the diagnosis of NSCLC. With high sensitivity and specificity of the combined detection,serum Cyfra 21-1 and CK19-2G2 levels are clinically useful in the diagnosis of NSCLC.